Published in Multidiscip Respir Med on December 11, 2012
The Emergent Landscape of Detecting EGFR Mutations Using Circulating Tumor DNA in Lung Cancer. Biomed Res Int (2015) 0.78
DNA sequencing with chain-terminating inhibitors. Proc Natl Acad Sci U S A (1977) 790.54
Global cancer statistics, 2002. CA Cancer J Clin (2005) 119.22
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med (2004) 71.08
EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science (2004) 61.56
Real time quantitative PCR. Genome Res (1996) 35.79
EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A (2004) 33.85
DNA sequencing with Thermus aquaticus DNA polymerase and direct sequencing of polymerase chain reaction-amplified DNA. Proc Natl Acad Sci U S A (1988) 14.20
Real-time DNA sequencing using detection of pyrophosphate release. Anal Biochem (1996) 12.94
Quantification of mRNA using real-time reverse transcription PCR (RT-PCR): trends and problems. J Mol Endocrinol (2002) 12.69
Advanced sequencing technologies: methods and goals. Nat Rev Genet (2004) 9.31
Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. Cancer Res (2004) 7.76
The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities. Eur J Cancer (2001) 5.96
EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. J Clin Oncol (2005) 5.07
Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation. Clin Cancer Res (2010) 3.68
Review of epidermal growth factor receptor biology. Int J Radiat Oncol Biol Phys (2004) 3.68
Detection of epidermal growth factor receptor mutations in serum as a predictor of the response to gefitinib in patients with non-small-cell lung cancer. Clin Cancer Res (2006) 3.66
Reverse transcription and DNA amplification by a Thermus thermophilus DNA polymerase. Biochemistry (1991) 3.54
Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer. Cancer Sci (2007) 3.52
Technical aspects of immunohistochemistry. Vet Pathol (2005) 3.51
A rapid and sensitive enzymatic method for epidermal growth factor receptor mutation screening. Clin Cancer Res (2006) 2.68
Biomarkers of response to epidermal growth factor receptor inhibitors in Non-Small-Cell Lung Cancer Working Group: standardization for use in the clinical trial setting. J Clin Oncol (2008) 2.51
The power of real-time PCR. Adv Physiol Educ (2005) 2.21
Mutation-specific antibodies for the detection of EGFR mutations in non-small-cell lung cancer. Clin Cancer Res (2009) 2.13
Denaturing high performance liquid chromatography (DHPLC) used in the detection of germline and somatic mutations. Nucleic Acids Res (1998) 1.99
Detection of EGFR gene mutation in lung cancer by mutant-enriched polymerase chain reaction assay. Clin Cancer Res (2006) 1.91
Epidermal growth factor receptor overexpression correlates with a poor prognosis in completely resected non-small-cell lung cancer. Ann Oncol (2004) 1.62
Rapid and sensitive nonradioactive detection of mutant K-ras genes via 'enriched' PCR amplification. Oncogene (1991) 1.59
Quantifying EGFR alterations in the lung cancer genome with nanofluidic digital PCR arrays. Clin Chem (2010) 1.53
A rapid, sensitive assay to detect EGFR mutation in small biopsy specimens from lung cancer. J Mol Diagn (2006) 1.50
EGFR Mutation status in Japanese lung cancer patients: genotyping analysis using LightCycler. Clin Cancer Res (2005) 1.47
The biology of epidermal growth factor receptor in lung cancer. Clin Cancer Res (2004) 1.46
Stratification of non-small cell lung cancer patients for therapy with epidermal growth factor receptor inhibitors: the EGFR fluorescence in situ hybridization assay. Diagn Pathol (2006) 1.37
Synchronous overexpression of epidermal growth factor receptor and HER2-neu protein is a predictor of poor outcome in patients with stage I non-small cell lung cancer. Clin Cancer Res (2004) 1.32
Pyrosequencing, a method approved to detect the two major EGFR mutations for anti EGFR therapy in NSCLC. J Exp Clin Cancer Res (2011) 1.25
Relationship of EGFR mutations, expression, amplification, and polymorphisms to epidermal growth factor receptor inhibitors in the NCI60 cell lines. Clin Cancer Res (2007) 1.20
Targeting the epidermal growth factor receptor in non-small cell lung cancer. Clin Cancer Res (2003) 1.15
Validation of chromogenic in situ hybridization for detection of EGFR copy number amplification in nonsmall cell lung carcinoma. Mod Pathol (2007) 1.10
Antibody-mediated EGF receptor blockade as an anticancer therapy: from the laboratory to the clinic. Cancer Immunol Immunother (2003) 1.08
Detection and comparison of epidermal growth factor receptor mutations in cells and fluid of malignant pleural effusion in non-small cell lung cancer. Lung Cancer (2007) 1.08
DNA amplification by the polymerase chain reaction. Anal Chem (1990) 1.05
Detection of codon 61 point mutations of the K-ras gene in lung and colorectal cancers by enriched PCR. Oncol Rep (2003) 1.01
A method to detect ras point mutations in small subpopulations of cells. Anal Biochem (1991) 0.93
Detection of epidermal growth factor receptor variations by partially denaturing HPLC. Clin Chem (2006) 0.92
DNA sequencing by denaturation: principle and thermodynamic simulations. Anal Biochem (2008) 0.85
Rapid detection of the epidermal growth factor receptor mutation in non-small-cell lung cancer for analysis of acquired resistance using molecular beacons. J Mol Diagn (2010) 0.85
Comparison of three methods for detecting epidermal growth factor receptor mutations in plasma DNA samples of Chinese patients with advanced non-small cell lung cancer. Chin Med J (Engl) (2011) 0.81
Immunohistochemical detection of mutated epidermal growth factor receptors in pulmonary adenocarcinoma. Anticancer Res (2010) 0.80
Detection of DNA mutations in acid formalin-fixed paraffin-embedded archival tumor specimens by polymerase chain reaction-single strand conformation polymorphism analysis. Cancer Detect Prev (1995) 0.78
Direct sequencing is more accurate and feasible in detecting single nucleotide polymorphisms than RFLP: using human vascular endothelial growth factor gene as a model. Biol Res Nurs (2007) 0.78
Colorimetric detection of mutations in epidermal growth factor receptor using gold nanoparticle aggregation. Biosens Bioelectron (2009) 0.77
Detection of epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer (NSCLC) using a fully automated system with a nano-scale engineered biomagnetite. Biosens Bioelectron (2006) 0.77
The polymerase chain reaction. Adv Physiol Educ (2004) 0.76
Gefitinib versus cetuximab in lung cancer: round one. J Natl Cancer Inst (2005) 0.76
Activity of MMP-2 and MMP-9 in sera of breast cancer patients. Pathol Res Pract (2010) 0.92
Immunochemotherapy for Bcl-2 and MUM-negative aggressive primary cutaneous B-cell non-Hodgkin's lymphoma. Arch Dermatol Res (2009) 0.90
Values of MMP-2 and MMP-9 in tumor tissue of basal-like breast cancer patients. Cell Biochem Biophys (2014) 0.89
Investigation of NK cell function and their modulation in different malignancies. Immunol Res (2012) 0.88
Lactate dehydrogenase, catalase, and superoxide dismutase in tumor tissue of breast cancer patients in respect to mammographic findings. Cell Biochem Biophys (2013) 0.85
FGF-R3 and OPG expression in patient with multiple myeloma following systemic sclerosis: case report and review of the literature. Int J Hematol (2011) 0.84
Distribution of mast cells in benign odontogenic tumors. Tumour Biol (2011) 0.84
Pure red cell aplasia associated with type I autoimmune polyglandular syndrome-successful response to treatment with mycophenolate mofetil: case report and review of literature. J Clin Pathol (2007) 0.82
Combination of narrow band imaging (NBI) and autofluorescence imaging (AFI) videobronchoscopy in endoscopic assessment of lung cancer extension. Med Oncol (2011) 0.82
Estrogens: mechanisms of neuroprotective effects. J Physiol Biochem (2012) 0.81
Expression of Bcl2L12 in chronic lymphocytic leukemia patients: association with clinical and molecular prognostic markers. Med Oncol (2013) 0.81
Antiproliferative effect of 13-cis-retinoic acid is associated with granulocyte differentiation and decrease in cyclin B1 and Bcl-2 protein levels in G0/G1 arrested HL-60 cells. Pathol Oncol Res (2010) 0.80
FLT3/D835 mutation and inversion of chromosome 16 in leukemic transformation of myelofibrosis. Eur J Intern Med (2006) 0.77
Optimization of PCR conditions for amplification of GC-Rich EGFR promoter sequence. J Clin Lab Anal (2013) 0.77
Estimation of cell membrane alteration after drug treatment by LDH release. Blood (2003) 0.76
The Prevalence of Spine Deformities and Flat Feet among 10-12 Year Old Children Who Train Basketball--Cross-Sectional Study. Coll Antropol (2015) 0.75
Standard versus extended lymphadenectomy in radical surgical treatment for pancreatic head carcinoma. J BUON (2017) 0.75
Rituximab for treatment of autoimmune hemolytic anemia. Indian Pediatr (2012) 0.75
Naturally occurring V region connected antibodies inhibit anti-dsDNA antibody reactivity with dsDNA. Immunobiology (2011) 0.75
Possibility of transformation of primary myelofibrosis to ALL without JAK2V617F mutation. Med Oncol (2013) 0.75
Orbital lymphoma with isolated occult bilateral adrenal involvement: report of an extremely rare case. Rom J Morphol Embryol (2016) 0.75
Prevalence of arterial hypertension in Serbia: PAHIS study. J Hypertens (2013) 0.75
The importance of choice of resection procedures in T1 and T2 stage of carcinoma of the ampulla of Vater. J BUON (2015) 0.75